Beam Therapeutics Inc. (BEAM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150M 300M 450M Q3 '21: 781K Q4 '21: 51.8M Q1 '22: 60.3M Q2 '22: 76.9M Q3 '22: 92M Q4 '22: 60.9M Q1 '23: 76.7M Q2 '23: 80.2M Q3 '23: 81.6M Q4 '23: 377.7M Q1 '24: 360.9M Q2 '24: 352.6M Q3 '24: 349.6M Q4 '24: 63.5M Q1 '25: 63.6M Q2 '25: 60.3M Q3 '25: 55.7M Q4 '25: 139.7M Q1 '26: 164M Q2 '26: 156M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '21: -369.8M Q4 '21: -392.5M Q1 '22: -268.3M Q2 '22: -291.3M Q3 '22: -313M Q4 '22: -338.5M Q1 '23: -361.2M Q2 '23: -381.4M Q3 '23: -398.3M Q4 '23: -176.5M Q1 '24: -181.7M Q2 '24: -184.4M Q3 '24: -182.7M Q4 '24: -415.6M Q1 '25: -430.7M Q2 '25: -446M Q3 '25: -466.3M Q4 '25: -383.7M Q1 '26: -371.6M Q2 '26: -378M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -401.4M Q4 '21: -370.6M Q1 '22: -238.3M Q2 '22: -234M Q3 '22: -315.4M Q4 '22: -289.1M Q1 '23: -316.3M Q2 '23: -327.2M Q3 '23: -313.7M Q4 '23: -132.5M Q1 '24: -134.7M Q2 '24: -143M Q3 '24: -143.6M Q4 '24: -376.7M Q1 '25: -386.4M Q2 '25: -397.5M Q3 '25: -413.6M Q4 '25: -80M Q1 '26: -66M Q2 '26: -86.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -92.4M Q4 '21: -66.3M Q1 '22: 190.8M Q2 '22: 171.1M Q3 '22: 93.5M Q4 '22: 22.5M Q1 '23: -305.8M Q2 '23: -338.2M Q3 '23: -353.5M Q4 '23: -149.2M Q1 '24: -139.1M Q2 '24: -137.5M Q3 '24: -135.8M Q4 '24: -347.2M Q1 '25: -351.4M Q2 '25: -344.8M Q3 '25: -338.2M Q4 '25: -345.1M Q1 '26: -369.7M Q2 '26: -359.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -134M Q4 '21: -113.1M Q1 '22: 148.2M Q2 '22: 123M Q3 '22: 39.5M Q4 '22: -26.4M Q1 '23: -353.5M Q2 '23: -380.4M Q3 '23: -391.9M Q4 '23: -182.9M Q1 '24: -169.3M Q2 '24: -153.4M Q3 '24: -145.4M Q4 '24: -356.2M Q1 '25: -361M Q2 '25: -355.6M Q3 '25: -352.4M Q4 '25: -360M Q1 '26: -383.8M Q2 '26: -372.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '20: 49.4M Q3 '20: 50.1M Q1 '21: 60.2M Q2 '21: 62.2M Q3 '21: 66.4M Q1 '22: 68.7M Q2 '22: 70.2M Q3 '22: 70.3M Q1 '23: 72.3M Q2 '23: 76.3M Q3 '23: 79M Q1 '24: 81.7M Q2 '24: 82.3M Q3 '24: 82.4M Q1 '25: 88M Q2 '25: 102M Q3 '25: 102.6M Q1 '26: 103.3M Q2 '26: 104.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '21: -6.88 Q4 '21: -5.91 Q1 '22: -3.57 Q2 '22: -3.36 Q3 '22: -4.50 Q4 '22: -4.13 Q1 '23: -4.45 Q2 '23: -4.51 Q3 '23: -4.17 Q4 '23: -1.72 Q1 '24: -1.60 Q2 '24: -1.63 Q3 '24: -1.58 Q4 '24: -4.58 Q1 '25: -4.60 Q2 '25: -4.49 Q3 '25: -4.42 Q4 '25: -0.81 Q1 '26: -0.49 Q2 '26: -0.67 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.